about
Cytohesins are cytoplasmic ErbB receptor activatorsThe LIM-only protein FHL2 reduces vascular lesion formation involving inhibition of proliferation and migration of smooth muscle cellsFrequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrenceCell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancerAnti-proliferative effect of cytohesin inhibition in gefitinib-resistant lung cancer cellsRITA displays anti-tumor activity in medulloblastomas independent of TP53 status.Circulating microRNAs (miRNA) in serum of patients with prostate cancer.Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.Web-based database for the management of tissue specimens in a transregional histological research facilityAnalysis of TET expression/activity and 5mC oxidation during normal and malignant germ cell development.A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies.Membranous CD24 expression as detected by the monoclonal antibody SWA11 is a prognostic marker in non-small cell lung cancer patients.Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity.Elp3 drives Wnt-dependent tumor initiation and regeneration in the intestine.Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group.MicroRNAs in the pathogenesis of neuroblastoma.Elp3 links tRNA modification to IRES-dependent translation of LEF1 to sustain metastasis in breast cancerBET bromodomain protein inhibition is a therapeutic option for medulloblastoma.Tuberous-sclerosis complex-related cell signaling in the pathogenesis of lung cancer.The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.Targeted Therapy for Neuroblastoma: ALK Inhibitors.Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy.Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancerThe Prosurvival IKK-Related Kinase IKKε Integrates LPS and IL17A Signaling Cascades to Promote Wnt-Dependent Tumor Development in the Intestine.Mutational dynamics between primary and relapse neuroblastomas.Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer.A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC.Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.Global levels of histone modifications predict prostate cancer recurrence.Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.TCam-2 but not JKT-1 cells resemble seminoma in cell culture.Implementing amplicon-based next generation sequencing in the diagnosis of small cell lung carcinoma metastases.Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci.Hippo signaling mediates proliferation, invasiveness, and metastatic potential of clear cell renal cell carcinoma.Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer.Correction: Elp3 drives Wnt-dependent tumor initiation and regeneration in the intestine.Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma.Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients with early stage breast cancer.
P50
Q24303022-9AF1A24D-7231-4737-9CC2-72A1BBB8E678Q27339876-FCF62438-C4E6-493D-A814-2615FEF01869Q27851615-E814080A-243F-4C5F-BB22-CF3E70B54FB4Q27851880-306B8BDC-7F74-473A-A77C-97002FE8D6ADQ28277232-478A576B-C6CE-4738-9A20-7E577F3B8E6BQ28303281-3501055F-E192-4C34-97D0-4FCDE9C2511CQ28729071-C3F17CFC-0324-412B-AAF7-469B981E2A11Q33709483-691B02A6-B4EF-48DB-B351-8BB234468A40Q34182161-C872ADC3-0353-41AC-BEDC-29FDA0376114Q34544677-42A1AF83-442D-4C60-BE32-886E97313ABCQ34704300-BE0E37CE-BB3E-4696-A7C3-82A86827AAE8Q35080075-F6C858F1-4051-4108-A0F9-4C532269CA69Q35804064-984E4157-A57B-4B18-97FF-3AD9E3372249Q35844656-07A7F30F-F06E-43F4-A1AB-D2DECCD12AA9Q36228558-8282F68F-C168-42EE-800D-2B0F781B9AFDQ36286025-EAFD48D0-A050-47E5-B190-931A78DA6A76Q36432090-C7714633-5471-4F16-BA93-B7FC3E21FD51Q37221138-5F3059BF-7894-4987-B006-C37D16589FFAQ37346677-21489A1C-DFD1-410A-84A1-B95B768285D5Q37420196-6DBBE62A-BF45-4636-8F89-C0AA418ECC9CQ37685008-1324BB41-049C-4F7F-8FAD-841A15A508F2Q37701672-CCBEC7EB-85B4-4242-B11C-BC587D272505Q38156044-A3036C66-77BB-48AD-B9E5-0527EB22F359Q38383404-AACAA7AC-9480-4583-A6DF-8442F476B60DQ38673369-CD0E6BD5-D6CB-4D0F-A0FB-BEC9192CC32BQ38785994-867A34EF-2DEB-415C-813F-A7BA9284CB12Q38859077-36451DCE-A4DE-4332-98E5-3C0985147377Q39011070-EE1E8962-59F3-4DAE-AA82-7C157DC55009Q39022113-1BBEB62C-6348-4DCD-BE2B-6B334FA32FB7Q39328851-E91EF2CE-0167-4C13-9D5C-A031030286DFQ39899696-15482F10-783B-4A9F-97A3-42BE454014DCQ39929331-B8FF47D7-F24E-4D3E-8F59-109433581716Q40050312-07E6B102-36DF-4C1D-9180-8D0035F76F19Q40346036-157038DC-0166-40A9-825C-9F4D2E32B646Q40414404-22EEB53A-C50F-4355-8DD9-245948E4AC9EQ41867443-EFCF51D3-28B3-4051-A932-A198697C40D8Q42153300-F2C86BB0-78F9-4B57-8B55-46E02BDD04C2Q42292865-BE7BECEA-5FC9-4E20-BCCA-1E516909B001Q42367759-9F925086-BA3D-4764-A311-CD67FE94821BQ42839175-46A2B6DF-437F-4A2C-B4E2-0DCEB104B79C
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Lukas C Heukamp
@ast
Lukas C Heukamp
@en
Lukas C Heukamp
@es
Lukas C Heukamp
@nl
type
label
Lukas C Heukamp
@ast
Lukas C Heukamp
@en
Lukas C Heukamp
@es
Lukas C Heukamp
@nl
prefLabel
Lukas C Heukamp
@ast
Lukas C Heukamp
@en
Lukas C Heukamp
@es
Lukas C Heukamp
@nl
P106
P21
P31
P496
0000-0002-3388-3482